Abstract
Medicines in the cancer therapeutic area account for the third largest source of revenue within the pharma industry. The cancer market has experienced significant innovative change in recent years, creating attractive opportunities for a range of new and established biotechnology players as well as established pharma companies. Although new product development continues to involve substantial levels of risk, innovation is the key driving force in the market, and has led to the competitive exclusion of several of the industry' s traditional competitors. With successful launches now being applied to multiple indications faster than ever before, subsequent increases in product sales volumes are rapidly changing the competitive landscape of the cancer market. The Cancer Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of the major markets in the global cancer area, incorporating a detailed epidemiological analysis of the nine major indications and key factors impacting their prevalence. Current leading brands of treatment within each cancer indication are analysed and eight of the market' s leading players are profiled. With coverage of over 9 % of the total market for cancer products, this report profiles the factors and underlying trends that are driving market transformation and identifies the most promising areas of potential growth. Forecasts for currently marketed and key pipeline products over the 2 6-12 period are also provided. Discover the key market trends and growth drivers of the cancer market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this new report.
Table of Contents
Executive Summary
- Patient potential
- Global market analysis
- Pipeline analysis
- Competitive landscape
Chapter 1 Epidemiology of cancer
- Summary
- Introduction
- Overview
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Colorectal cancer
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Breast cancer
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Ovarian cancer
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Uterine and cervical cancer
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Leukemia
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Prostate cancer
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Pancreatic cancer
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast prevalence
- Lymphomas
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast prevalence
Chapter 2 Global market analysis
- Summary
- Introduction
- Market analysis by country
- Trends in generics usage and licensing
- Market analysis by drug class
- Leading brands dynamics
- Key events in the cancer market
- Antineoplastics
- Competitive dynamics of antineoplastics
- Leading brands of antineoplastics
- Antineoplastic MAb market analysis
- Market dynamics
- Key brands analysis
- Vinka alkaloid market analysis
- Market dynamics
- Key brands analysis
- Anti-metabolites
- Market dynamics
- Key brands analysis
- Other antineoplastics
- Market dynamics
- Antineoplastic sales forecasts to 2012
- Immunostimulants
- Competitive dynamics of immunostimulants
- Leading brands of immunostimulants
- Interferon market analysis
- Market dynamics
- Key brands analysis
- Other immunostimulants
- Market dynamics
- Key brand analysis
- Immunostimulant sales forecasts to 2012
- Cytostatic hormonal therapies
- Competitive dynamics of cytostatic hormonal therapies
- Leading brands of cytostatic hormonal therapies
- LHRH agonists market analysis
- Market dynamics
- Key brands analysis
- Aromatase inhibitors
- Market dynamics
- Key brands analysis
- Anti-estrogens
- Market dynamics
- Key brand analysis
- Anti-androgens
- Cytostatic hormonal therapy sales forecasts to 2012
- Total cancer market sales forecasts to 2012
Chapter 3 Pipeline analysis
- Summary
- Introduction
- Key trends in R&D
- Need for drugs with improved tumor selectivity
- Increased focus on cancer vaccine pipeline
- Cost containment policies emerging as barrier for drug development
- The cancer pipeline
- Leading drugs in development
- Profiles of key pipeline products
- Phase III compounds
- Enzastaurin
- BiovaxID
- HuMax-CD20 (ofatumumab)
- Recentin (cediranib)
- Zactima (vandetanib)
- Recently approved/marketed drugs
- Tasigna (nilotinib)
- Gardasil and Cervarix
- Vectibix (panitumumab)
- Nexavar (sorafenib)
- Sutent (sunitinib)
- Tykerb (lapatinib)
- Pipeline forecasts
- Factors affecting forecasts
- Cancer therapeutic area forecasts
Chapter 4 Competitive landscape
- Summary
- Introduction
- Company market shares
- Roche
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Amgen
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Sanofi-Aventis
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- AstraZeneca
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Novartis
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Pfizer
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Schering-Plough
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Eli Lilly
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
Chapter 5 Appendix
- IMS data
- Antineoplastic and immunomodulating agents
- L1: Cytostatics
- L2: Cytostatic hormone therapy
- L3: Immunostimulating agents
- Licensing status as per IMS Health
- Original brand
- Other brand
- Licensed brand
- Not-coded product
- Unbranded/ generic product
- Index
List of Figures
- Figure 1.1: Overview of cancer etiology
- Figure 2.2: Worldwide cancer market share by geography, 2006
- Figure 2.3: Sales of cancer brands by license type, 2005-06
- Figure 2.4: Competitive dynamics of the global cancer market by drug class, 2006
- Figure 2.5: Competitive dynamics of the leading brands in the global cancer market, 2005-06
- Figure 2.6: Competitive dynamics of the major antineoplastic classes in the global cancer market, 2005-06
- Figure 2.7: Competitive dynamics of leading brands in the antineoplastic market, 2005-06
- Figure 2.8: Competitive dynamics of the major immunostimulant classes in the global cancer market, 2005-06
- Figure 2.9: Competitive dynamics of the leading brands in the global cancer immunostimulant market, 2005-06
- Figure 2.10: Competitive dynamics of the major cytostatic hormonal therapy classes in the global cancer market, 2005-06
- Figure 2.11: Competitive dynamics of the leading brands in the global cytostatic hormonal therapy market, 2005-06
- Figure 3.12: Driver and resistors in cancer R&D, 2007
- Figure 3.13: Oncology pipeline by indication and stage of development, 2006
- Figure 3.14: Recently launched products and late-stage R&D compounds indicated for the treatment of cancer, 2006
- Figure 4.15: Competitive dynamics of the leading players in the global cancer market, 2006
- Figure 4.16: Roche' s cancer sales by drug class, 2006
- Figure 4.17: Amgen' s cancer sales by drug class, 2006
- Figure 4.18: Sanofi-Aventis' cancer sales by drug class, 2006
- Figure 4.19: AstraZeneca' s cancer sales by drug class, 2006
- Figure 4.20: Novartis' cancer sales by drug class, 2006
- Figure 4.21: Pfizer' s cancer sales by drug class, 2006
- Figure 4.22: Schering-Plough' s cancer sales by drug class, 2006
- Figure 4.23: Lilly' s cancer sales by drug class, 2006
List of Tables
- Table 1.1: Estimated prevalence of lung cancer across the seven major markets, 2006
- Table 1.2: Forecast epidemiology of lung cancer across the seven major markets, 2006-12
- Table 1.3: Estimated epidemiology of colorectal cancer across the seven major markets, 2006
- Table 1.4: Forecast epidemiology of colorectal cancer across the seven major markets, 2006-12
- Table 1.5: Estimated epidemiology of breast cancer across the seven major markets, 2006
- Table 1.6: Forecast epidemiology of breast cancer across the seven major markets, 2006-12
- Table 1.7: Estimated epidemiology of ovarian cancer across the seven major markets, 2006
- Table 1.8: Forecast epidemiology of ovarian cancer across the seven major markets, 2006-12
- Table 1.9: Estimated epidemiology of uterine cancer across the seven major markets, 2006
- Table 1.10: Forecast epidemiology of uterine cancer across the seven major markets, 2006-12
- Table 1.11: Estimated epidemiology of leukemia across the seven major markets, 2006
- Table 1.12: Forecast epidemiology of leukemia across the seven major markets, 2006-12
- Table 1.13: Estimated epidemiology of prostate cancer across the seven major markets, 2006
- Table 1.14: Forecast epidemiology of prostate cancer across the seven major markets, 2006-12
- Table 1.15: Estimated epidemiology of pancreatic cancer across the seven major markets, 2006
- Table 1.16: Forecast epidemiology of pancreatic cancer across the seven major markets, 2006-12
- Table 1.17: Estimated epidemiology of lymphomas across the seven major markets, 2006
- Table 1.18: Forecast epidemiology of lymphomas across the seven major markets, 2006-12
- Table 2.19: Breakdown of the global cancer market by drug class, 2003-06
- Table 2.20: Leading products in the global cancer market, 2005-06
- Table 2.21: Breakdown of the global antineoplastic market by drug class,
- Table 2.22: Leading therapies in the global antineoplastics market, 2005-06
- Table 2.23: Antineoplastic sales forecast, 2006-12
- Table 2.24: Breakdown of the global immunostimulant market by drug class, 2003-06
- Table 2.25: Leading therapies in the global immunostimulant market, 2005-06
- Table 2.26: Immunostimulant sales forecast, 2006-12
- Table 2.27: Global cytostatic hormonal therapy market by drug class, 2003-06
- Table 2.28: Leading therapies in the global cytostatic hormonal therapy market, 2005-06
- Table 2.29: Cytostatic hormonal therapy sales forecast, 2006-12
- Table 2.30: Cancer sales forecasts by drug class, 2006-112
- Table 3.31: Cancer pipeline sales forecasts, 2006-12
- Table 4.32: Leading players in the cancer market, 2005-06
- Table 4.33: Roche' s cancer product portfolio, 2005-06
- Table 4.34: Roche' s cancer R&D product pipeline, 2007
- Table 4.35: Amgen' s cancer product portfolio, 2005-06
- Table 4.36: Amgen' s cancer R&D product pipeline, 2007
- Table 4.37: Sanofi-Aventis' cancer product portfolio, 2005-06
- Table 4.38: Sanofi-Aventis' cancer R&D product pipeline, 2007
- Table 4.39: AstraZeneca' s cancer product portfolio, 2005-06
- Table 4.40: AstraZeneca' s cancer R&D product pipeline, 2007
- Table 4.41: Novartis' cancer product portfolio, 2005-06
- Table 4.42: Novartis' cancer R&D product pipeline, 2007
- Table 4.43: Pfizer' s cancer product portfolio, 2005-06
- Table 4.44: Pfizer' s cancer R&D product pipeline, 2007
- Table 4.45: Schering-Plough' s cancer product portfolio, 2005-06
- Table 4.46: Schering-Plough' s cancer R&D product pipeline, 2007
- Table 4.47: Lilly' s cancer product portfolio, 2005-06
- Table 4.48: Lilly' s cancer R&D product pipeline, 2007
